Cardium Announces Follow-On Direct Investment by Institutiona... (issue (bone) andsoft tissue (ligament te...)

Cardium Announces Follow-On Direct Investment by Institutional Investor

Date:6/30/2008

issue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study will be reproduced in subsequent studies, that our products or proposed products will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that having a shelf registration statement in place will allow the Company to take advantage of favorable market conditions or that the Company will be effectively able to sell additional common stock on favorable terms. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected quali
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Cardium Selected for Inclusion in Russell Microcap Index
2. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
3. Cardium Launches New AWARE Clinical Study Website
4. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
5. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
6. Cardium Reports on First Quarter 2008 Highlights and Financial Results
7. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
8. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
9. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
10. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
11. Cardium Completes $5.3 Million Registered Direct Offering

Post Your Comments:

Cardium Announces Follow-On Direct Investment by Institutiona...(issue (bone) andsoft tissue (ligament te...)